Aged ≥18 years (inclusive of the boundary value), with no restriction on gender.
Expected survival time of at least 3 months.
Subjects with refractory moderate - to - severe active rheumatoid arthritis who have failed standard treatment or lack effective therapeutic options.
Meet the requirements for liver and kidney function, as well as cardiopulmonary function.
Free from severe psychiatric disorders.
Able to understand the trial and have signed the informed consent form.
You may not be if
A history of malignant tumors other than relapsed/refractory autoimmune diseases (R/R AID) within 5 years prior to screening.
Subjects with positive results in virus/syphilis tests.
Severe cardiac diseases or unstable systemic diseases.
Active or uncontrollable infections requiring systemic treatment within 7 days before administration; evidence of central nervous system invasion at screening.
Pregnant or breastfeeding women, female subjects planning to become pregnant within 2 years after cell infusion, or male subjects whose partners plan to become pregnant within 2 years after their cell infusion.
Subjects who have received CAR - T therapy or other gene - modified cell therapies before screening.
Subjects who participated in other clinical studies within 1 month before screening.
Other conditions deemed unsuitable for enrollment by the investigator.
